NCT04322552View on ClinicalTrials.gov

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

April 3, 2021

Study Completion Date

May 3, 2021

Conditions

Advanced Solid Tumor

Interventions

DRUG

Apatinib Mesylate

Apatinib at a dosage of will be administered daily from on D5 through D16

DRUG

Digoxin tablet

Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12

Trial Locations (1)

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04322552 - A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects | Biotech Hunter | Biotech Hunter